DUBLIN, May 4, 2015 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading specialty biopharmaceutical company, will present on Wednesday, May 13, 2015, at the Bank of America Merrill Lynch 2015 Health Care Conference at Encore at the Wynn hotel in Las Vegas, Nev.
Matthew Harbaugh, Senior Vice President and Chief Financial Officer, and Cole Lannum, Senior Vice President of Investor Strategy and Investor Relations Officer, will represent the company in a session scheduled to begin at 3 p.m. Eastern / noon Pacific.
Individuals who cannot attend the meeting in person can find webcast information on Mallinckrodt's Investor Relations website at http://mallinckrodt.com/investor_relations. A replay will also be available following the meeting.
Mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology; neonatal critical care respiratory therapies; and analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines and devices; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. The company's fiscal 2014 revenue totaled $2.54 billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Senior Vice President, Communications and Public Affairs
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO
Vice President, Investor Relations
SOURCE Mallinckrodt Pharmaceuticals